Trial Profile
Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs MV CEA (Primary) ; MV NIS (Primary)
- Indications Adenocarcinoma; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 28 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Jan 2013 Planned end date changed from 1 Jul 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 07 Dec 2012 New source identified and integrated (Mayo Clinic).